MedPath

Feasibility of exercise to improve insulin sensitivity in postmenopausal women who are overweight or obese receiving chemotherapy for breast cancer

Not Applicable
Conditions
Insulin sensitivity in overweight/obese postmenopausal women receiving chemotherapy for breast cancer
Nutritional, Metabolic, Endocrine
Registration Number
ISRCTN14544863
Lead Sponsor
niversity of Wolverhampton
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Ongoing
Sex
Female
Target Recruitment
40
Inclusion Criteria

1. Females who are postmenopausal (not experiencing menstrual periods for the previous 12 months via self-report) and aged between 45 and 69 years: as determined by self-report. Participants will be asked to answer whether they are pre-, peri-, or post-menopausal. If they have answered ‘post-menopausal’, they will be asked to recall when their final menstrual cycle was.
2. Diagnosed with stage I-III breast cancer with an ECOG performance status grade of 0-2 as deemed by the oncology team at the time of diagnosis.
3. Have a body mass index (BMI) of 25 to 39.9 (i.e., overweight, or obese) kg/m2, or if Asian or South Asian a BMI of 23 to 39.9 kg.m2, respectively. BMI will be taken from patient notes.
4. Scheduled to undergo chemotherapy treatment for breast cancer under oncology supervision: determined by the oncology team.
5. No medical conditions prohibiting exercise as deemed by the oncologist.
6. Not engaging in regular exercise (i.e., meeting current physical activity recommendations of at least 150 min per week of moderate exercise or at least 75 min per week of vigorous exercise, or an equivalent combination of moderate and vigorous exercise). This criterion will be assessed via the Physical Activity Vital Signs (PAVS) questionnaire, which asks the following two questions: 1) please describe your level of physical activity, [first by] minutes per day, [followed by] number of days each week”, and 2) at what intensity (how hard): light (like a casual walk), moderate (like a brisk walk), or vigorous (like a jog/run)?” (Ball et al., 2016). The questionnaire is scored by multiplying the days by minutes of physical activity to create an estimate of minutes per week of at least moderate-to-vigorous physical activity. This will be done verbally over the phone.
7. Able to communicate in English and able to provide and understand informed consent determined over the telephone by a trained researcher.

Exclusion Criteria

1. Separate diagnosis of cancer within five years prior to the study (not breast cancer) as deemed by the oncology team
2. Secondary or metastatic breast cancer as deemed by the oncology team
3. Plans for reconstructive surgery during the study period expressed by the potential participant during discussions with the oncology team
4. Not fluent in written or spoken English
5. Symptoms of long COVID/post-COVID syndrome via self-report questionnaire
6. A diagnosis of type 2 diabetes or any other co-morbidity (i.e., hypertension, hypercholesterolemia, cardiovascular disease) determined via self-report
7. Taking metformin determined via self-report

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Feasibility as assessed by recruitment rate (40 patients in 12 months), retention rate (at least 70%), and adherence to exercise (at least 67% of sessions completed)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath